Niagen Bioscience to Streamline and Focus its Operations with the Sale of ChromaDex Reference Standards Business to LGC in All-Cash Transaction

Core Insights - Niagen Bioscience has announced the sale of its ChromaDex Reference Standards business to LGC in an all-cash transaction, aimed at streamlining operations and focusing on core activities related to NAD+ science and healthy aging [1] Company Strategy - The divestiture is part of Niagen Bioscience's strategy to exit non-core activities and allocate resources towards NAD+ science, intellectual property, and commercial growth within the longevity industry [1] - CEO Rob Fried emphasized that this transaction allows the company to focus on advancing NAD+ science and delivering patented Niagen® solutions [1] Acquisition Details - The sale to LGC is expected to enhance LGC's capabilities in supporting pharmaceutical customers, testing laboratories, and food producers by expanding their reference materials and analytical standards portfolio [1] - LGC Standards, a division of LGC Group, is recognized as a global leader in life sciences and analytical solutions [1] Market Position - Niagen Bioscience is positioned as a leader in NAD+ science and healthy aging research, with a focus on innovative NAD+-boosting solutions [1] - The company’s flagship product, Niagen®, is noted as the most efficient and well-researched NAD+ booster available [1] Future Outlook - Niagen Bioscience is dedicated to advancing healthspan through precision science and innovative solutions, with a robust patent portfolio protecting its NAD+ precursors [1]